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Dear Editor: We read with interest the paper by Sonden 
et al. [1] confirming the large increase in numbers of 
Plasmodium vivax cases diagnosed in Europe during 
the years 2014 and 2015, mainly due to newly arrived 
Eritrean migrants. Using the GeoSentinel surveillance 
network data, we recently published similar trends 
with regards to P. vivax in Eritrean migrants present-
ing in Europe but also in Israel [2]. Among 146 Eritrean 
migrants with malaria presenting at GeoSentinel clin-
ics between 1999 through September 2017, the pro-
portion of P. vivax infections was 84.2% (123/146), 
followed by P. falciparum (12/146; 8.2%), which does 
not reflect the local epidemiology in Eritrea, where 
there is a large predominance of P. falciparum reported 
[3,4]. A further point of interest was finding four cases 
of P. ovale (4/146; 2.7%) and one case of P. malariae 
(1/146, 0.7%) when the proportion of these two species 
is 0.02% of all malaria cases in studies conducted in 
Eritrea [4]. The remaining six cases were either mixed 
P. vivax/P. falciparum infections or unknown species. 
Among 100 patients with information available, 69 
(69%) presented with symptoms after arrival and the 
median time between arrival in the host country and 
presentation was 39 days; 31/100 (31%) of migrants 
reported malaria symptoms while in transit. Among P. 
vivax infections, we also reported 4% (5/123) cases of 
severe P. vivax malaria.
This situation raises several important questions – 
where do the Eritrean migrants get infected with malaria 
on their migration route? Our study [2] proposed that 
the acquisition of P. vivax likely occurred somewhere 
underway, possibly in Sudan or Ethiopia, or perhaps 
even in camps in Libya, a country that is currently 
considered malaria-free; this question is of medical 
and epidemiological importance. Competent malaria 
vectors are present in Libya and as camps are popu-
lated with migrants, some of whom may be infected by 
Plasmodium spp. including P. vivax, the possibility that 
malaria may be transmitted in such camps should be 
considered – and investigated by entomological sur-
veys, despite the challenge that it may represent.
Early diagnosis and correct management of malaria in 
Eritrean migrants is necessary to avoid severe disease 
and the potential reintroduction of malaria in recep-
tive European areas. Primaquine treatment i.e. 15(−30) 
mg base per day for 14 days, is indicated to prevent 
relapses by hypnozoite elimination; it is considered 
standard of care to test for G6PD deficiency in all per-
sons before use of primaquine. We conducted a sur-
vey among GeoSentinel clinics regarding availability of 
primaquine and G6PDH deficiency testing. Our results 
were that in several European countries, primaquine is 
only available through hospital pharmacies or through 
an international pharmacy with delays in procurement 
and results of testing may take days (1-14 days) [2]. 
Point of care G6PDd tests are largely unavailable. The 
procurement logistics and long therapy duration with 
primaquine as well as the need for pre-treatment G6PD 
screening in a potentially ‘hard-to-reach’ population 
call for a specific policy to address malaria in Eritrean 
migrants.
Based on published literature [5], the infectious dis-
eases most frequently reported in Eritrean migrants 
(besides malaria) are louse-borne relapsing fever, 
scabies with secondary bacterial infections, tuber-
culosis and schistosomiasis. Such infections (except 
schistosomiasis) likely result from the overcrowding, 
poor hygienic conditions, exposure to arthropods and 
risks for transmission of tuberculosis that are typically 
experienced by migrants during their long migration 
process. Thus, screening for infectious diseases and 
differential diagnosis in both asymptomatic and ill 
migrants should take in account both the endemicity of 
diseases in the origin country and the risks faced along 
the migration routes and in holding camps.
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